Skip to content
Oligomerix
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Therapeutic Areas
  • Pipeline
    • OLX07010 in Rare Tauopathies
    • OLX07010 Alzheimer’s
  • Technology
    • MOA
    • Patents
  • News & Publications
  • Partners and Collaborators
  • Contact Us
Menu
  • News
  • Presentations
  • Publications
  • Media Coverage
  • Media Kit
  • Archive News

News & Publications

Oligomerix > News & Publications
  •   
  • Print
Oligomerix > News & Publications
+ Expand all
News

    Presentations

    Preclinical Review and Initial Clinical Plan Overview for Oligomerix's Small Molecule Lead Tau Inhibitor
    Oligomerix BIO Europe presentation video, October 2021

    Novel, First-In-Class Small Molecule Inhibitors Targeting Tau for Neurodegeneration
    Video Presentation: BIO Virtual, June 2021

    Novel, First-In-Class Small Molecule Inhibitors Targeting Tau for Neurodegeneration
    Slide Deck: BIO Virtual, June 2021

    Publications
    Davidowitz EJ, Krishnamurthy PK, Lopez P, Jimenez H, Adrien L, Davies P, Moe JG (2020). In Vivo Validation of Small Molecule Inhibitor of Tau Self-Association in htau Mice. Journal of Alz, vol. 73, no. 1, pp. 147-161, 2020.
    Fá M, Puzzo D, Piacentini R, Staniszewski A, Zhang H, Baltrons MA, Li Puma DD, Chatterjee I, Li J, Saeed F, Berman HL, Ripoli C, Gulisano W, Gonzalez J, Tian H, Costa JA, Lopez P, Davidowitz E, Yu WH, Haroutunian V, Brown LM, Palmeri A, Sigurdsson EM, Duff KE, Teich AF, Honig LS, Sierks M, Moe JG, D’Adamio L, Grassi C, Kanaan NM, Fraser PE, Arancio O. (2016) Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory. Sci Rep 6, 19393.
    Tian H, Davidowitz E, Lopez P, He P, Schulz P, Moe J, Sierks MR (2015). Isolation and characterization of antibody fragments selective for toxic oligomeric tau. Neurobiol Aging 36, 1342-55.
    Tian H, Davidowitz E, Lopez P, Emadi S, Moe J, Sierks M (2013) Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations. Int J Cell Biol. 2013:260787.
    Davidowitz EJ, Chatterjee I, Moe JG (2008) Targeting tau oligomers for therapeutic development for Alzheimer’s disease and tauopathies. Curr Topics Biotechnol 4, 47-64.

    Abstracts

    Moe, James G. et al. In vivo efficacy of a small molecule inhibitor of tau oligomer formation in htau mice. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2018, Volume 14, Issue 7, P1527 – P1528.
    Moe, James G. et al. CNS drug-like inhibitors of tau oligomerization. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2017, Volume 13, Issue 7, P1580.
    Moe, James G. et al. Small molecule tau oligomerization inhibitors. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2016, Volume 12, Issue 7, P434.
    Krishnamurthy, Pavan K. et al. Characterization of tool compounds targeting tau oligomers. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2015, Volume 11, Issue 7, P906.
    Moe, James G. et al. Drug development of inhibitors of tau oligomer formation for Alzheimer’s disease and tauopathies. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2014, Volume 10, Issue 4, P865 – P866.
    Moe, James et al. Small-molecule lead identification for inhibition of tau oligomer formation. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2013, Volume 9, Issue 4, P891.
    Davidowitz, Eliot et al. Characterization of a novel monoclonal antibody specific for a tau autoproteolytic cut site that differentiates between Alzheimer’s disease and non-Alzheimer’s specimens. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2013, Volume 9, Issue 4, P308.
    Moe, James G. et al. Extracellular oligomeric tau inhibits memory formation in mice. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2010, Volume 6, Issue 4, S277.
    Moe, James G. et al. Modulation of synaptic function by extracellular tau enriched in oligomers. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2009, Volume 5, Issue 4 , P499.
    Media Coverage

      Media Kit

      Coming Soon!

      Archive News

        Oligomerix, Inc.
        2 Westchester Park Drive, Suite 208
        White Plains, NY 10604

        917-912-4088

        • About
        • Management
        • Board of Directors
        • Scientific Advisory Board
        • Pipeline
        • OLX07010 in Rare Tauopathies
        • OLX07010 Alzheimer’s
        • Technology
        • MOA
        • Patents
        • Therapeutic Areas
        • News & Publications
        • Partners and Collaborators
        • Contact Us
        • Site Map
        © Copyright 2022 Oligomerix. All Rights Reserved.
        FCOI Policy
        Website by Axxiem
        Scroll to top
        By accessing our website or software provided by our third-party vendors, you consent to accept cookies, (including other identifiers). These include pieces of text that are stored on your computer or device. This site uses cookies and Google Analytics to improve navigation, minimize the need to reenter information previously entered on forms, personalize messages, and collect statistical information to improve site navigation and provide content of greatest interest to users.Ok
        close ×